Quick Answer
Tanke Biosciences Corp reported Total Revenue of $28.56 million for fiscal year 2012.
Tanke Biosciences Corp — Key Financials by Year
| Metric | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|
| Total Revenue | $28.56M +19.8% |
$23.83M +18.6% |
$20.10M | — | — |
| Net Income | -$210.2K +93.3% |
-$3.14M -214.5% |
$2.74M | — | — |
| Diluted EPS | — | -$0.24 -170.6% |
$0.34 | — | — |
| Total Assets | $28.85M +15.9% |
$24.89M +87.6% |
$13.27M | — | — |
| Cash and Equivalents | $6.17M -19.9% |
$7.70M +246.5% |
$2.22M +22.2% |
$1.82M | — |
| Long-Term Debt | $792.6K +26.1% |
$628.4K +38.7% |
$453.0K | — | — |
| Stockholders Equity | $15.75M -0.6% |
$15.85M +94.2% |
$8.16M +26.8% |
$6.44M +70.5% |
$3.77M |
| Operating Income | $4.53M +160.6% |
$1.74M -60.2% |
$4.37M | — | — |
| Gross Profit | $9.94M +13.4% |
$8.77M +18.5% |
$7.40M | — | — |
| Shares Outstanding | 13.32M +0.0% |
13.32M +23.9% |
10.76M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2013 | $6.04M | -39.0% | +8.3% |
| Net Income | September 30, 2013 | -$302.1K | -131.2% | -355.6% |
| Diluted EPS | September 30, 2012 | $0.07 | +163.6% | +240.0% |
| Total Assets | September 30, 2013 | $28.81M | -0.1% | -2.2% |
| Cash and Equivalents | September 30, 2013 | $5.05M | -54.2% | +7.0% |
| Long-Term Debt | September 30, 2013 | $732.6K | -22.7% | -9.4% |
| Stockholders Equity | September 30, 2013 | $15.56M | -5.9% | -1.0% |
| Operating Income | September 30, 2013 | -$530.3K | -124.3% | -454.3% |
| Gross Profit | September 30, 2013 | $1.69M | -50.0% | -7.2% |
| Shares Outstanding | September 30, 2013 | 13.32M | +0.0% | +0.0% |
- Tanke Biosciences Corp reported Total Revenue of $28.56 million for fiscal year 2012.
- Tanke Biosciences Corp showed an increase of +19.8% in Total Revenue compared to the prior fiscal year.
- Tanke Biosciences Corp reported Net Income of -$210.2 thousand for fiscal year 2012.
- Tanke Biosciences Corp showed an increase of +93.3% in Net Income compared to the prior fiscal year.
- Tanke Biosciences Corp reported Diluted EPS of $0.24 per share (loss) for fiscal year 2011.
- Tanke Biosciences Corp showed a decrease of -170.6% in Diluted EPS compared to the prior fiscal year.
- Tanke Biosciences Corp reported Total Assets of $28.85 million for fiscal year 2012.
- Tanke Biosciences Corp showed an increase of +15.9% in Total Assets compared to the prior fiscal year.
- Tanke Biosciences Corp reported Cash and Equivalents of $6.17 million for fiscal year 2012.
- Tanke Biosciences Corp showed a decrease of -19.9% in Cash and Equivalents compared to the prior fiscal year.
- Tanke Biosciences Corp reported Long-Term Debt of $792.6 thousand for fiscal year 2012.
- Tanke Biosciences Corp showed an increase of +26.1% in Long-Term Debt compared to the prior fiscal year.
- Tanke Biosciences Corp reported Stockholders Equity of $15.75 million for fiscal year 2012.
- Tanke Biosciences Corp showed a decrease of -0.6% in Stockholders Equity compared to the prior fiscal year.
- Tanke Biosciences Corp reported Operating Income of $4.53 million for fiscal year 2012.
- Tanke Biosciences Corp showed an increase of +160.6% in Operating Income compared to the prior fiscal year.
- Tanke Biosciences Corp reported Gross Profit of $9.94 million for fiscal year 2012.
- Tanke Biosciences Corp showed an increase of +13.4% in Gross Profit compared to the prior fiscal year.
- Tanke Biosciences Corp reported Shares Outstanding of 13.32 million shares for fiscal year 2012.
- Tanke Biosciences Corp showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: